- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03447873
Tripe Versus Dual Antiretroviral Therapy in HIV-infected Patients With Virological Suppression (Tridual) (Tridual)
Is Dual Therapy as Effective as Triple Therapy Regarding CD4+/CD8+ Ratio Recovery and Improvement of Immune Activation and Inflammation in HIV-infected Patients With Consistent Plasma Viral Load Suppression (Tridual)
The persistence of an aberrant state of immune activation and inflammation (pIA) may contribute to the emergence of serious non-AIDS events which carry a higher morbimortality in HIV-infected patients. Although combined antiretroviral treatment (cART) reduces both cellular and soluble activation markers, it fails to completely control pIA despite consistent plasma viral load suppression. One of the mechanisms involved in pIA is may be an incomplete suppression of viral replication not reflected by plasma viral load, which only reflects a balance between viral replication and clearance of HIV-RNA. In addition, low-level viremia detected in most HIV-1-infected patients despite years on cART. Unintegrated 2-LTR HIV-DNA, and cellular associated HIV-RNAs, as products of active integrated DNA transcription, support this issue.
Furthermore, the key rationales behind simplifying cART are a reduction of toxicities, lower risk of resistance mutations in case of virological failure and saving costs. One of these simplification strategies is a dual therapy which, based on the data up to date and in our clinical experience, has similar virological efficacy than cART. However, it is unknown if this strategy could increase the persistent HIV-1 replication and, therefore, pIA. The CD4+/CD8+ T cell ratio as a marker of immune recovery, the changes in T cell immune activation, senescence, exhaustion and apoptosis, and the cellular associated HIV-DNA and -RNA would answer the question if simplification to dual therapy would provide less control of residual HIV replication and, therefore, a detriment on pIA compared to triple therapy and, therefore, would worsen the patients' long-term prognosis.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Primary Outcome Measures: to evaluate the changes in the CD4/CD8 ratio, immune activation and other immunologic parameters at 48 weeks after switching to dual therapy based on dolutegravir plus emtricitabine o darunavir/cobicistat plus emtricitabine versus to continue on triple therapy based on integrase inhibitor plus 2 analogs Secondary Outcome Measures: to evaluate the changes in the CD4/CD8 ratio, immune activation and other immunologic parameters at 96 weeks after switching to dual therapy based on dolutegravir plus emtricitabine o darunavir/cobicistat plus emtricitabine versus to continue on triple therapy based on integrase inhibitor plus 2 analogs
Method: randomized clinical trial in which adult HIV-infected patients with an undetectable plasma HIV-RNA for at least one year on a triple therapy based on integrase inhibitors plus two nucleos(t)ide analogs will be randomized in 3 groups (1:1:1) with 4 strata according to the previous time with undetectable viral load to:
Continue the previous ART based on Elvitegravircobicistat 150150 mg + tenofovir alafenamide 10 mg + emtricitabine 200 mg (Genvoya™) o Dolutegravir 50 mg + abacavir 600 mg + lamivudine 300 mg (Triumeq™) once daily.
Or to switch to:
- Darunavir/cobicistat (800150 mg) + 3TC (300 mg) once daily or
- Dolutegravir (50 mg) + 3TC (300 mg) once daily.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Sevilla, Spain, 41013
- Virgen del Rocio University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- HIV-1-infected patients ≥ 18 years of age.
- Starting date of antiretroviral treatment later than 01/01/2010
- Plasma HIV-1 RNA <20 copies/ml for at least one year on triple therapy
- Antiretroviral treatment based on an integrase inhibitor plus two nucleos(t)ide analogs in the last 6 months.
- Signed written informed consent prior to inclusion.
Exclusion Criteria:
- Primary resistance to any of the drugs included in the study.
- Active opportunistic infection.
- Pregnancy at inclusion or during the follow-up
- Active hepatitis C and/or B virus co-infection.
- Cirrhosis, portal hypertension and/or hypersplenism of any etiology.
- Current or past malignancies subsidiary of treatment with corticosteroids, immunomodulatory agents, interferon or chemotherapeutic agents.
- Any laboratory abnormality grade 3 or 4 according to the U.S. Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Division of AIDS.
- Concomitant use of drugs with potential major interactions with the prescribed drugs according to the respective full prescribing information.
- Estimated creatinine clearance <50 ml/min
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Triple therapy
To Continue with triple therapy with Elvitegravir/cobicistat + tenofovir alafenamide + emtricitabine or Dolutegravir + abacavir + lamivudine once daily.
|
To continue with triple therapy
|
Experimental: Switch to dual therapy A
Switch to dual therapy with Darunavir/cobicistat (800150 mg) + lamivudine (300 mg) once daily once daily.
|
Switch to dolutegravir + lamivudine once daily
|
Experimental: Switch to dual therapy B
Switch to dual therapy with Dolutegravir (50 mg) + lamivudine (300 mg) once daily
|
Switch to darunavir/cobicistat + lamivudine once daily
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
CD4/CD8 ratio
Time Frame: 48 weeks
|
To evaluate if a triple therapy based on integrase inhibitors plus two nucleos(t)ide analogs will provide a higher CD4+/CD8+ T cell ratio recovery compared with dual therapies based on darunavir/cobicistat plus lamivudine or dolutegravir plus lamivudine after 48 weeks of treatment in HIV-infected patients with consistent plasma viral load suppression.
|
48 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Immune activation
Time Frame: 48 weeks
|
To assess whether dual therapies provide an increase in immune activation and inflammation compared to triple therapy assessed by the expression of HLA-DR and CD38 in both of CD4+ and CD8+ T cells and sCD14 after 48 weeks of treatment.
|
48 weeks
|
Collaborators and Investigators
Collaborators
Investigators
- Study Director: Luis F Lopez-Cortes, PhD, Virgen del Rocio University Hospital. Seville. Spain
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- HIV Infections
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Reverse Transcriptase Inhibitors
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Anti-HIV Agents
- Anti-Retroviral Agents
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 Enzyme Inhibitors
- Cobicistat
- Lamivudine
Other Study ID Numbers
- FIS-TAR-01-2016
- 2016-005226-11 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
-
Boston Children's HospitalNational Institute on Minority Health and Health Disparities (NIMHD)Completed
Clinical Trials on Continue with triple therapy
-
Chengdu University of Traditional Chinese MedicineCompletedFailure After Assisted Reproductive TechnologyChina
-
Chengdu University of Traditional Chinese MedicineCompletedFailure After Assisted Reproductive TechnologyChina
-
Universidad de los Andes, ChileMunicipalidad de Lo Barnechea, ChileRecruiting
-
University of ZurichCompletedObstructive Sleep ApnoeaSwitzerland
-
Shanghai Junshi Bioscience Co., Ltd.WithdrawnPrimary Condition: Advanced TumorsChina
-
Kaohsiung Medical UniversityCompletedHelicobacter Pylori InfectionTaiwan
-
Universitaire Ziekenhuizen KU LeuvenAZ Sint-Jan AV; General Hospital Groeninge; Universiteit AntwerpenRecruiting
-
Federal University of São PauloFundação de Amparo à Pesquisa do Estado de São PauloCompletedHelicobacter Pylori Infection | Immune Thrombocytopenic PurpuraBrazil
-
National Jewish HealthCompletedCystic FibrosisUnited States
-
Fudan UniversityRecruitingHelicobacter Pylori Infection | MALT Lymphoma of StomachChina